vincristine

P2, N=60, Active, not recruiting, National Hospital Organization Nagoya Medical Center | Recruiting --> Active, not recruiting

P2, N=32, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting

Catharanthus roseus is an important medicinal plant and the only source of the important anticancer compounds vincristine and vinblastine. Ascorbate peroxidase activity generally decreased below control levels, except in 4% CE for 78 h its activity increased slightly and reached the control levels. In conclusion, our results show that CF demonstrates a stronger elicitor than CE, particularly at higher concentrations and longer exposure, for inducing defense responses in C. roseus cell suspension culture.

P3, N=1000, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed

P3, N=683, Recruiting, University Hospital Muenster | Trial completion date: Nov 2027 --> Apr 2030 | Trial primary completion date: Nov 2027 --> Apr 2030

Genetic or pharmacological inhibition of IRE1α or spliced XBP1 (sXBP1) suppresses cell proliferation, promotes terminal myogenic differentiation, and enhances vincristine-induced cytotoxicity in RMS cells...Consistently, inducible knockdown of sXBP1 or pharmacological inhibition of IRE1α endonuclease activity significantly attenuates xenograft RMS growth. Collectively, these findings identify the IRE1α-XBP1 axis as a critical regulator of RMS growth, differentiation, and chemosensitivity, and support its therapeutic targeting in RMS.

P3, N=330, Recruiting, Shanghai Children's Medical Center | Trial primary completion date: Mar 2026 --> Mar 2027

Genetic or pharmacological inhibition of IRE1α or spliced XBP1 (sXBP1) suppresses cell proliferation, promotes terminal myogenic differentiation, and enhances vincristine-induced cytotoxicity in RMS cells...Consistently, inducible knockdown of sXBP1 or pharmacological inhibition of IRE1α endonuclease activity significantly attenuates xenograft RMS growth. Collectively, these findings identify the IRE1α-XBP1 axis as a critical regulator of RMS growth, differentiation, and chemoresistance, and support its therapeutic targeting in RMS.

The patient was promptly started on neoadjuvant chemotherapy (VAC + IE [vincristine, adriamycin, cyclophosphamide, ifosfamide, and etoposide]), which he tolerated well without significant adverse effects. Given the aggressive nature of renal EWS, a multimodal treatment approach involving chemotherapy followed by radical nephrectomy is essential for improving prognosis. This case sheds light on the importance of considering renal EWS in the differential diagnosis of renal masses and emphasizes the role of early intervention in enhancing survival outcomes.

P3, N=479, Completed, Children's Oncology Group | Active, not recruiting --> Completed

P2, N=340, Active, not recruiting, Merck Sharp & Dohme LLC | N=243 --> 340

To examine the involvement of centrosome clustering in the mechanism by which BATF2 reverses MDR in GC, adriamycin (ADR)- and vincristine (VCR)-resistant cell lines, NCI-N87/ADR and NCI-N87/VCR, were used for investigations. Meanwhile, KU-60019, a specific inhibitor of ATM, could markedly reverse the pro-tumor effects of BATF2 knockdown. In conclusion, BATF2 is a potential target for reversing MDR in GC, and targeting KIFC1-related centrosome clustering by suppressing ATM phosphorylation is proposed as a key mechanism.